Teon Therapeutics is a private biopharma start-up developing a portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that is superior to other candidates like AB928 and AZD4635, and will enter Phase 1b trials in 2021. Our experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan and Ranexa, which led to the acquisition of CV Therapeutics by Gilead for $1.4B. We are currently raising a Series A that will help achieve multiple clinical milestones in the next 24 months.
Overview presentation here:
https://teonthera.egnyte.com/dl/MpAMqy0i5n
Overview presentation here:
https://teonthera.egnyte.com/dl/MpAMqy0i5n
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
TT-702 (A2BR antagonist)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
